346 articles by Gwendolyn Wu

• Medicxi closes sixth fund to back ‘asset-centric’ startups

  Nov. 14, 2025

• Lilly picks up an eye gene therapy in deal with MeiraGTx

  Nov. 10, 2025

• AstraZeneca exercises option to buy an obesity startup

  Nov. 6, 2025

• Evommune nabs $150M in IPO amid federal shutdown

  Nov. 5, 2025

• Corporate venture firms stepped in for drug startups during biotech funding pullback

  Oct. 31, 2025

• Zag Bio emerges with plans to treat immune disease by targeting the thymus

  Oct. 28, 2025

• Electra nabs $183M for its rare disease drug ambitions

  Oct. 22, 2025

• Flagship bets again on AI with Expedition

  Oct. 22, 2025

• Cancer drug startup Tubulis raises $361 million for ADCs

  Oct. 15, 2025

• A young biotech nets $70M for a new type of allergy drug

  Oct. 13, 2025

• Evommune files for IPO to advance immune drug work

  Oct. 10, 2025

• MapLight uses workaround to tee up IPO during government shutdown

  Oct. 7, 2025

• Chiesi buys into Arbor gene editing drug for rare kidney disease

  Oct. 6, 2025

• Cartography secures $67M in pursuit of ‘differentiated’ cancer drugs

  Oct. 2, 2025

• Crystalys debuts with $205M and plans for a better gout drug

  Sept. 30, 2025

• Star raises another $125M for its blood disease drug

  Sept. 30, 2025

• Sanofi Ventures banks $625M to back young biotechs, digital health startups

  Sept. 24, 2025

• Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’

  Sept. 23, 2025

• MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug

  Sept. 22, 2025

• A new biotech venture firm emerges, led by Bob Langer’s son

  Sept. 18, 2025

• Ollin debuts with $100M and plans to challenge top-selling eye drugs

  Sept. 17, 2025

• Former CinCor execs reunite to helm new biotech startup

  Sept. 16, 2025

• LB Pharmaceuticals raises $285M in first major biotech IPO since February

  Sept. 10, 2025

• Lilly to give biotech startups access to AI tools

  Sept. 9, 2025

• A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

  Sept. 8, 2025

• Atlas Venture reels in $400M to grow its biotech startups

  Sept. 4, 2025

• A drug discovery startup banks $150M for immune and obesity drugs

  Sept. 4, 2025

• Startup Corsera Health aims to bring preventive heart medicine to the masses

  Sept. 2, 2025

• FDA approves Ionis’ hereditary angioedema drug

  Aug. 21, 2025

• Omega’s Otello Stampacchia on the ‘reset’ changing biotech for the better

  Aug. 19, 2025

• Strand raises another $153M to make ‘programmable’ mRNA drugs

  Aug. 7, 2025

• Xoma strikes deals to buy struggling biotechs HilleVax, Lava

  Aug. 4, 2025

• Venture firm Frazier closes $1.3B fund for early-stage biotech investing

  July 31, 2025

• Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

  July 29, 2025

• Bristol Myers shuffles its executive ranks with new CMO

  July 25, 2025

• A TCG offshoot pulls in $400M for biotech startup creation

  July 24, 2025

• Biotech startup funding dried up in second quarter, HSBC finds

  July 17, 2025

• AstraZeneca rare disease drug fails key trial tests

  July 16, 2025

• Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding

  July 10, 2025

• Actithera draws new investors to radiopharma drug pitch

  July 9, 2025

• Protein degraders: chasing undruggable targets

  July 8, 2025

• Study results boost Cogent’s case for rare disease drug

  July 7, 2025

• Sage to lay off most staff amid Supernus buyout

  June 30, 2025

• Vor, with new CEO, changes course to target autoimmune disease

  June 26, 2025

• Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

  June 25, 2025

• Lexeo to help launch spinout around RNA drugs for the heart

  June 24, 2025

• A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups

  June 20, 2025

• Draig, a brain drug startup, debuts with $140M to treat depression

  June 18, 2025

• A startup banks $66M to pursue ‘inclusive precision medicine’

  June 18, 2025

• SpliceBio lands $135M for a new kind of eye gene therapy

  June 11, 2025

• National Resilience, a well-funded manufacturing startup, to scale back operations

  June 10, 2025

• Kymera, with new data, takes early step toward a Dupixent-like pill

  June 2, 2025

• Cancer drugmaker iTeos to shut down

  May 28, 2025

• GlycoEra raises $130M, riding interest in protein degraders

  May 27, 2025

• Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

  May 19, 2025

• AbbVie stakes $335M on a startup’s RNAi drugs

  May 15, 2025

• Novo to work with Septerna in hunt for oral obesity drugs

  May 14, 2025

• Siren, a gene therapy startup, tests unconventional alternative to venture funding

  May 1, 2025

• Novartis to acquire Regulus in deal for kidney disease drug

  April 30, 2025

• FDA misses approval deadline for biotech’s rare disease drug

  April 29, 2025

• Versant startup Granite debuts with $100M and 2 immune drugs

  April 24, 2025

• Etiome, a new Flagship startup, looks to catch disease before it strikes

  April 24, 2025

• Roche looks to a Flagship startup in search of new immune drugs

  April 23, 2025

• An investment fund sets out to free biotech’s ‘trapped capital’

  April 18, 2025

• Bluebird says Ayrmid missed deadline for rival takeover bid

  April 16, 2025

• Startup Glycomine raises $115M to push rare disease drug deeper into testing

  April 16, 2025

• Third Harmonic outlines plans for dissolution

  April 14, 2025

• Tango Therapeutics cuts nearly one-fifth of staff

  April 7, 2025

• Biotech ‘megarounds’ hold steady as startups, VCs wait on IPOs

  April 3, 2025

• RNA editing biotech Airna adds $155M in funding

  April 1, 2025

• Isomorphic raises $600M on big ambitions for AI drugmaking tech

  March 31, 2025

• Epicrispr banks $68M to test epigenetic editing on rare muscle disease

  March 26, 2025

• Character Biosciences raises $93M with an eye on vision loss drugs

  March 25, 2025

• Verve gets FDA green light to expand base editing trial into US

  March 24, 2025

• Cargo shelves cell therapy research, lays off more staff

  March 19, 2025

• Sofinnova’s latest biotech fund sprouts three new startups

  March 18, 2025

• Arbor raises $74M amid genetic medicine’s funding slump

  March 18, 2025

• Flagship startup raises $200M in pursuit of ‘scientific superintelligence’

  March 12, 2025

• Sofinnova secures €1.2B for new biotech investments

  March 4, 2025

• Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

  March 3, 2025

• Eikon raises $351M in one of the year’s largest biotech venture rounds

  Feb. 26, 2025

• ‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts

  Feb. 25, 2025

• Recursion CEO launches pre-seed fund in response to NIH cuts

  Feb. 19, 2025

• Immune drugmakers Alumis and Acelyrin to merge

  Feb. 7, 2025

• Vertex challenger Sionna prices $191M IPO

  Feb. 6, 2025

• Flagship-backed Omega signals it’s headed toward bankruptcy

  Feb. 4, 2025

• Metsera, Maze secure combined $415 million in IPOs

  Jan. 30, 2025

• Cargo to drop lead CAR-T therapy, lay off staff after study setback

  Jan. 30, 2025

• Atalanta banks $97M to send RNAi drugs into the brain

  Jan. 28, 2025

• Ascentage prices first biotech IPO of 2025, raising $126M

  Jan. 23, 2025

• JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

  Jan. 16, 2025

• JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

  Jan. 14, 2025

• 5 questions facing emerging biotech in 2025

  Jan. 14, 2025

• JPM25: Deals, Summit’s bravado and gene therapy headwinds

  Jan. 13, 2025

• Tune raises $175M for hepatitis B medicine, epigenetic research

  Jan. 12, 2025

• Kidney disease drugmaker Maze files for IPO

  Jan. 8, 2025

• Orbis raises $93M to turn popular biologics into pills

  Jan. 6, 2025

• A venture firm breathes new life into an old NGM drug

  Dec. 19, 2024

• Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery

  Dec. 11, 2024

• Gene therapy uptake in sickle cell stays slow, despite patient interest

  Dec. 9, 2024

• BioAge shares tumble after decision to halt obesity drug study

  Dec. 7, 2024

• Nuvig pulls in $161M to make better immune drugs

  Dec. 5, 2024

• Biotech startups are built on venture capital. Track funding rounds here.

  Nov. 21, 2024

• Versant startup sets out to make a new type of obesity drug

  Nov. 21, 2024

• Chasing new ‘checkpoints,’ startup Valora emerges from a Nobel winner’s lab

  Nov. 20, 2024

• Flagship, Pfizer alliance yields two more startup deals

  Nov. 20, 2024

• TRex Bio raises $84M to compete in crowded immune drug field

  Nov. 13, 2024

• GSK partners with Flagship startup to hunt for Parkinson’s drugs

  Nov. 12, 2024

• An RNAi renaissance is creating a new generation of startups

  Nov. 6, 2024

• Evommune raises $115M to accelerate immune drug tests

  Oct. 31, 2024

• A new biotech, built around protein design, springs from David Baker’s lab

  Oct. 30, 2024

• With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs

  Oct. 27, 2024

• GPCR drugmaker Septerna amasses $288M in IPO

  Oct. 24, 2024

• J&J’s Asish Xavier on biotech’s rebound in a volatile era

  Oct. 24, 2024

• RNA editing: emerging from CRISPR’s shadow

  Oct. 22, 2024

• Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug

  Oct. 10, 2024

• AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines

  Oct. 9, 2024

• Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney

  Oct. 7, 2024

• With $115M more, Triveni accelerates immune drug work

  Oct. 2, 2024

• Kailera Therapeutics emerges from stealth with $400M for obesity drugs

  Oct. 1, 2024

• Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science

  Sept. 26, 2024

• BioAge prices $198M IPO, validating pivot to obesity drug research

  Sept. 25, 2024

• An Italian biotech gets $52M to advance pediatric gene therapies

  Sept. 25, 2024

• Nura Bio gets $68M, new CEO to advance ‘neuroprotective’ brain drugs

  Sept. 17, 2024

• ArsenalBio raises $325M in one of the year’s largest biotech funding rounds

  Sept. 4, 2024

• Cell and gene therapy investment, once booming, is now in a slump

  Aug. 29, 2024

• Versant’s Jerel Davis on build-to-buy deals and pharma investment

  Aug. 26, 2024

• Two antibody startups file for IPOs amid summer slump

  Aug. 23, 2024

• Versant reimagines its Chinook success with newest startup launch

  Aug. 22, 2024

• With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships

  Aug. 9, 2024

• Biotech startup Airna raises $60M for RNA editing medicines

  July 31, 2024

• GSK leans on Flagship for help finding new drugs, vaccines

  July 29, 2024

• Autobahn raises $100M on investor interest in neuropsych drugs

  July 24, 2024

• Private biotech M&A surges amid difficult IPO market

  July 22, 2024

• Vertex taps Orum to hunt for better ‘preconditioning’ drugs

  July 16, 2024

• SciRhom pulls in $70M for a new type of immune disease drug

  July 9, 2024

• A London biotech raises $114M to hone a new ADC payload

  July 8, 2024

• ​​​​​​​Alumis cuts IPO size, but nets $250M for immune drug work

  June 28, 2024

• AbbVie expands its IBD prospects with $250M Celsius deal

  June 27, 2024

• Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine

  June 25, 2024

• Roche partners with RNA editing biotech Ascidian

  June 18, 2024

• Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.

  June 18, 2024

• Versant debuts biotech working on ‘anger management for the immune system’

  June 13, 2024

• Foresite, a biotech venture firm, reloads with $900M fund

  June 12, 2024

• As biotech recovers, venture firms’ preferences appear to shift

  June 6, 2024

• Eli Lilly adds ALS drug prospect with QurAlis deal

  June 3, 2024

• CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs

  May 30, 2024

• SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca

  May 22, 2024

• AltruBio lands up to $225M after shift to immune drug research

  May 21, 2024

• Pheon rides wave of ADC interest with $120M financing

  May 21, 2024

• Investors put $400M into biotech licensing obesity drugs from China

  May 16, 2024

• Ajax, aiming for a better JAK drug, raises $95M to begin first tests

  May 13, 2024

• Novo taps another Flagship startup in search for next obesity drugs

  May 9, 2024

• Prologue, Flagship’s newest startup, looks to mine viruses for new drugs

  May 7, 2024

• CG follows big IPO with new results for bladder cancer drug

  May 3, 2024

• Delphia starts up with $67M to make a new type of cancer drug

  May 2, 2024

• Enlaza gets JP Morgan, Regeneron backing for covalent biologics

  April 30, 2024

• Repertoire pivot pays dividends with Bristol Myers deal

  April 29, 2024

• Regeneron expands in gene editing with Mammoth deal

  April 25, 2024

• Endeavor pulls in $132M to back cancer, lung disease drugs

  April 24, 2024

• Canaan hires Pfizer executive, reels in $100M for biotech investing

  April 17, 2024

• Biotech landlord Alexandria on research clusters and the sector’s recovery

  April 16, 2024

• Biotech IPOs bounced back in first quarter, but backlog remains

  April 12, 2024

• Vertex to buy kidney disease drugmaker Alpine for $4.9B

  April 10, 2024

• Private biotech funding rises as venture firms deploy cash

  April 8, 2024

• Diagonal starts up with $128M to make better ‘activator’ antibody drugs

  April 3, 2024

• Ginkgo, in search of more cell therapy tools, buys another startup

  April 2, 2024

• Boundless Bio breaks IPO lull with $100M fundraise

  March 28, 2024

• SQZ, Portal founder Armon Sharei on starting over in biotech

  March 26, 2024

• Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off

  March 21, 2024

• Clasp launches with $150M and a plan for precision cancer immunotherapies

  March 20, 2024

• German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing

  March 14, 2024

• Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO

  March 7, 2024

• European VC Invivo readies its latest fund to back new biotechs

  March 6, 2024

• Sionna raises another $182M to challenge Vertex in cystic fibrosis

  March 6, 2024

• Biotech IPOs heated up to start 2024. Will the surge last?

  March 5, 2024

• Nocion, chasing GSK, pulls in $62M for chronic cough drug

  March 4, 2024

• FogPharma pulls in $145M to support cancer drug research

  March 1, 2024

• Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup

  Feb. 28, 2024

• Frontier gets $80M, Galapagos’ backing to make a better KRAS drug

  Feb. 22, 2024

• Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

  Feb. 16, 2024

• Versant-backed Firefly Bio wants to make the next generation of ADCs

  Feb. 15, 2024

• ADC startup ProfoundBio, led by Seagen veterans, raises $112M

  Feb. 13, 2024

• Two GV investors on biotech’s reset and building their next drug startups

  Feb. 13, 2024

• Gene editing biotech Metagenomi pulls off nearly $94M IPO

  Feb. 8, 2024

• Venture firm Scion Life Sciences launches with $310M to back new biotechs

  Feb. 7, 2024

• Khosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery

  Feb. 6, 2024

• Brain drug developer Alto Neuroscience prices $129M IPO

  Feb. 2, 2024

• CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech

  Jan. 24, 2024

• Pharmas back Accent’s plan to make RNA-targeting cancer drugs

  Jan. 23, 2024

• A South Korean investment firm starts first US biotech fund

  Jan. 18, 2024

• Recursion’s Chris Gibson on AI in biotech and ‘virtuous cycles’

  Jan. 12, 2024

• Venture funding, dealmaking slowed in biotech last year: Pitchbook

  Jan. 11, 2024

• JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense

  Jan. 10, 2024

• JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job

  Jan. 8, 2024

• 5 questions facing emerging biotech in 2024

  Jan. 8, 2024

• Gene editing startup Metagenomi files for an IPO

  Jan. 6, 2024

• Intellia to lay off staff, cut some early research

  Jan. 4, 2024

• A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome

  Jan. 4, 2024

• Pivotal Life Sciences reloads with $389M, hunting for deals in a downturn

  Dec. 18, 2023

• At ASH, doctors acclaim new sickle cell gene therapies, but are cautious on details

  Dec. 13, 2023

• ASH23: Pharma branding, Editas’ high bar and clinical trial diversity

  Dec. 11, 2023

• Pfizer marks progress for successor sickle cell drug at ASH

  Dec. 10, 2023

• Bluebird gene therapy, now approved for sickle cell, shows durable benefit in study update

  Dec. 9, 2023

• BrainChild Bio spins out of Seattle Children’s to develop cancer drugs

  Dec. 5, 2023

• Flagship outlines plans to raise $3B for new fund

  Nov. 30, 2023

• Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024

  Nov. 28, 2023

• Flagship-backed microbiome biotech Evelo to shut down

  Nov. 22, 2023

• Quotient emerges from Flagship with plan to explore somatic mutations

  Nov. 21, 2023

• Roche’s Genentech partners with Nvidia in AI drug deal

  Nov. 21, 2023

• West Coast investor Red Tree on its San Diego expansion and staying bullish in biotech

  Nov. 16, 2023

• Ajinomoto spices up its biopharma business with gene therapy deal

  Nov. 13, 2023

• CAR-T biotech Cargo Therapeutics prices $281M IPO

  Nov. 10, 2023

• An obesity drug biotech gets buy-in from Eli Lilly, venture firms

  Nov. 7, 2023

• Bristol Myers pays $100M for a different kind of ADC

  Nov. 6, 2023

• Bioluminescence Ventures debuts with $477M to speed up drug discovery

  Nov. 1, 2023

• A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy

  Oct. 31, 2023

• Abingworth raises $356M to invest in late-stage drug development

  Oct. 30, 2023

• Triveni emerges from biotech merger with $92M for immune disease drugs

  Oct. 26, 2023

• An OrbiMed-backed biotech launches with $85M and plans for a new kind of DNA medicine

  Oct. 24, 2023

• Laronde, Senda Biosciences merge to create new Flagship company

  Oct. 19, 2023

• Intellia cleared by FDA to start Phase 3 test of gene editing treatment

  Oct. 18, 2023

• With $56M, a Mayo Clinic-backed startup takes aim at radiopharmaceutical roadblocks

  Oct. 17, 2023

• Novo’s Uli Stilz on biotech innovation and the future of diabetes drugs

  Oct. 17, 2023

• A decade later, biotech’s CRISPR revolution is still going strong

  Oct. 11, 2023

• UniQure lays off 20% of staff, cuts research to ‘significantly’ lower costs

  Oct. 5, 2023

• How biotech IPOs performed in the third quarter

  Oct. 3, 2023

• Novo Nordisk, Evotec partner in metabolic disease drug discovery pact

  Sept. 26, 2023

• Intarcia’s diabetes drug-device combo voted down again by FDA panel

  Sept. 21, 2023

• Genentech takes up a deal to make ‘molecular glue’ drugs

  Sept. 20, 2023

• Startup Airna emerges from stealth to bring RNA editing to a rare disease

  Sept. 19, 2023

• RayzeBio, Neumora price some of biotech’s largest IPOs this year

  Sept. 14, 2023

• Flagship-backed Generate raises $273M as its first drugs move to the clinic

  Sept. 14, 2023

• With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’

  Sept. 12, 2023

• Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise

  Sept. 6, 2023

• Star Therapeutics adds another $90M to grow its galaxy of drug startups

  Sept. 5, 2023

• Intarcia, a former biotech unicorn, gets new life with startup deal

  Aug. 30, 2023

• Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt

  Aug. 28, 2023

• Neumora, a richly funded brain drug developer, readies for an IPO

  Aug. 25, 2023

• Radiopharmaceutical drugmaker RayzeBio signals plans to go public

  Aug. 25, 2023

• Foundery, a new biotech venture firm, sets out to speed early immune drug research

  Aug. 22, 2023

• In a year with few biotech IPOs, ‘crossover’ financings are hard to find

  Aug. 16, 2023

• Alltrna raises $109M for ‘transfer RNA’ drug vision

  Aug. 9, 2023

• Steve Jobs’ son raises $200M for cancer-focused venture fund

  Aug. 2, 2023

• Early-stage biotech funding on pace to drop 40% in 2023, HSBC report shows

  July 28, 2023

• European VC Medicxi raises $400M for ‘asset-centric’ biotech investing

  July 27, 2023

• Nexo allies with MD Anderson in pursuit of covalent cancer drugs

  July 26, 2023

• Editas names Biogen veteran as top scientist in latest executive change

  July 24, 2023

• Pfizer, Flagship join forces to hunt for 10 new drugs

  July 18, 2023

• Sanofi expands research deal with gene editing startup Scribe

  July 17, 2023

• Apogee, Sagimet price IPOs in positive sign for sluggish biotech market

  July 14, 2023

• Rupert Vessey, former Bristol Myers exec, to join Flagship as top scientist

  July 13, 2023

• ‘It’s felt like Groundhog Day’: Biotech IPO slump drags on through 2023

  July 6, 2023

• F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn

  June 30, 2023

• Lilly to acquire cancer antibody drug startup Emergence

  June 29, 2023

• Startup Tagworks raises $65M to make ‘click-to-release’ cancer drugs

  June 22, 2023

• Flagship’s latest startup aims to take the guesswork out of small molecule drugs

  June 21, 2023

• Attovia, a new California biotech, launches with plans to rethink how drugs bind their targets

  June 20, 2023

• Cell and gene therapy manufacturing: the next generation of startups

  June 20, 2023

• Startup Eikon, led by Merck vets, buys drugs from three biotechs and banks another $106M

  June 1, 2023

• Atea rejects takeover bid from Concentra

  May 30, 2023

• Serial biotech founder Tim Springer on investing in startups and democratizing antibody research

  May 26, 2023

• Concentra bids on Atea, seeking to acquire another struggling biotech

  May 23, 2023

• ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs

  May 23, 2023

• Biotech Scribe strikes gene editing deal with Lilly subsidiary

  May 16, 2023

• Flagship’s newest startup is imitating nature to make new drugs

  May 16, 2023

• Nido debuts with $109M for its precision approach to brain drugs

  May 15, 2023

• FibroGen grabs an option to buy cancer drug startup Fortis

  May 9, 2023

• Recursion to acquire two Canadian drug discovery startups

  May 8, 2023

• Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021

  May 4, 2023

• Ovid partners with Waksal startup to develop drugs for rare brain disorders

  May 1, 2023

• Sanofi strikes a $150M deal for Maze’s Pompe disease drug

  May 1, 2023

• A startup taking a different approach to Alzheimer’s gets fresh funds, Lilly backing

  April 27, 2023

• Orbital raises $270 million in biotech’s largest Series A round this year

  April 26, 2023

• GV’s Cathy Friedman on optimism in biotech and the pitches that make her wary

  April 18, 2023

• A stealth biotech startup is quietly advancing a new drugmaking tool from David Liu’s lab

  April 5, 2023

• New biotech investor Cure Ventures closes first fund, raising $350M

  April 4, 2023

• After an ‘amazing year,’ SR One raises $600M to fuel more drug startups

  March 27, 2023

• Biotech startups face ‘Series A cliff’ as venture capital stays cautious

  March 24, 2023

• At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders

  March 22, 2023

• With focus on fibrosis, startup Mediar draws big pharma backing

  March 15, 2023

• SVB’s failure was contained. Its effects on biotech could still linger.

  March 14, 2023

• Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’

  March 14, 2023

• Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug

  March 9, 2023

• Flagship’s latest startup emerges with a plan for ‘smarter biologics’

  March 7, 2023

• GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins

  March 7, 2023

• Amid industry turbulence, Chroma raises fresh funding to edit the epigenome

  March 1, 2023

• Biotech veteran Jodie Morrison on building drug ‘platforms’ and a support group for CEOs

  Feb. 21, 2023

• With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s delivery problem

  Feb. 16, 2023

• A new generation of biotech leaders is emerging. Can they change how drug startups are built?

  Feb. 14, 2023

• Another biotech IPO hits the market, as Mineralys raises $192M

  Feb. 9, 2023

• Magenta to explore sale, merger after study setback

  Feb. 3, 2023

• Biotech startup Structure pulls off rare IPO, raising $161M

  Feb. 2, 2023

• A startup launches with plans to open up a gene and cell therapy bottleneck

  Jan. 31, 2023

• Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

  Jan. 24, 2023

• JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor

  Jan. 11, 2023

• JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas

  Jan. 10, 2023

• 5 questions facing emerging biotech in 2023

  Jan. 10, 2023

• Sesen, Carisma merger plans draw shareholder opposition

  Jan. 4, 2023

• Belharra debuts with $130M in funding, Genentech partnership

  Jan. 4, 2023

• FDA halts planned trial of Entrada Duchenne drug

  Dec. 20, 2022

• A San Diego startup sees covalent biologics as the next frontier in cancer drugs

  Dec. 15, 2022

• Flagship’s Lovisa Afzelius on creating a successful biotech and a ‘very different’ startup market

  Dec. 13, 2022

• Dantari emerges with a new way to make cancer drug conjugates

  Dec. 8, 2022

• Star Therapeutics launches Vega, growing its galaxy of drug startups

  Dec. 6, 2022

• With $81M, Entact Bio takes a new approach to fixing helpful proteins

  Dec. 6, 2022

• Gene editing startup iECURE returns to investors for fresh funding

  Nov. 30, 2022

• CinCor shares dive after blood pressure drug fails key trial

  Nov. 28, 2022

• Cancer drugmaker Plexxikon gets new life as Opna Bio

  Nov. 21, 2022

• Former Rubius CEO to lead buzzy Flagship startup

  Nov. 17, 2022

• Jnana deepens ties with Roche and grabs a new round of funding

  Nov. 15, 2022

• After $250M Roche buyout, a startup plans a second strike with fresh funding

  Nov. 15, 2022

• Acrivon cuts IPO price to raise $99M for plan to revive old Lilly cancer drug

  Nov. 15, 2022

• Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs

  Nov. 15, 2022

• Third Rock-backed Faze Medicines shutters two years after launch

  Nov. 10, 2022

• Artiva cancels IPO plans and cuts a deal with Affimed

  Nov. 3, 2022

• Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

  Nov. 3, 2022

• Armed with $120M, HI-Bio joins race to develop better autoimmune disease drugs

  Nov. 1, 2022

• An unusual alliance opens a gene and cell therapy hub outside Boston

  Oct. 27, 2022

• Verge Genomics’ Alice Zhang on a young biotech founder’s ‘superpower’ and going from target to drug

  Oct. 25, 2022

• Prime Medicine raises $175M in one of the year’s largest biotech IPOs

  Oct. 20, 2022

• A startup plans an IPO to give a shelved Lilly drug another shot

  Oct. 19, 2022

• Treeline Bio deepens investor roots with fresh funding for cancer drug research

  Oct. 17, 2022

• Covalent drugs take the stage — again — in Atlas Venture’s latest startup

  Oct. 14, 2022

• Ascidian starts up with $50M and a twist on RNA editing

  Oct. 12, 2022

• Brain disease startup Neumora draws more funding for ambitious research plan

  Oct. 11, 2022

• New TYK2 inhibitors: a growing race to top Bristol Myers

  Oct. 11, 2022

• A Flagship startup secures $121M in new funding

  Oct. 4, 2022

• Incyte, branching out in dermatology, to buy startup Villaris

  Oct. 3, 2022

• Ventus sells its lead drug candidate to Novo Nordisk

  Sept. 29, 2022

• Sudo joins a wave of startups taking aim at Bristol Myers’ new skin disease drug

  Sept. 28, 2022

• Perlara CEO Ethan Perlstein on reviving a biotech and building a ‘Y Combinator of rare diseases’

  Sept. 27, 2022

• Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street

  Sept. 21, 2022

• Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch

  Sept. 19, 2022

• Acelyrin sets hopes high for arthritis drug with $300M fundraise

  Sept. 14, 2022

• Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug

  Sept. 12, 2022

• Mitochondrial drugs, with a twist: Pretzel Therapeutics launches with $72.5M in funding

  Sept. 12, 2022

• Beam-linked startup launches with an eye on the next generation of RNA drugs

  Sept. 7, 2022

• Drugging RNA with pills: small molecules for a big frontier

  Sept. 6, 2022

• Atlas Venture’s Bruce Booth on testing the IPO waters and putting the ‘tech’ in biotech

  Aug. 30, 2022

• Bluejay raises $41M to bring hepatitis B drugs to clinical testing

  Aug. 19, 2022

• Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise

  Aug. 16, 2022

• Gemini’s fall gives Disc a way around biotech’s IPO slump

  Aug. 10, 2022

• A biotech startup gives Merck its next shot at treating Alzheimer’s

  Aug. 9, 2022

• How a small UK biotech ended up in Gilead’s hands

  Aug. 5, 2022

• Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

  Oct. 26, 2020